Olgu Sunumu
BibTex RIS Kaynak Göster

Diagnostic value of FDG-PET/CT in the detection of synchronous cancers

Yıl 2017, Cilt: 34 Sayı: 2, 137 - 140, 08.09.2017

Öz


Synchronous cancer refers to a new primary cancer in a person with a history of

malignant disease. It may be easily missed in early stages of its development.

Besides its high sensitivity in the diagnosis of malignant disease, FDG-PET/

CT has a technical advantage due to routinely performed whole-body scanning

procedures in the detection of synchronous cancers. In this case report, we discussed

two cases in which synchronous cancer was incidentally detected by







FDG-PET/CT whole body examination.






Kaynakça

  • Chopra, A., Ford, A., De Noronha, R., Matthews, S., 2012. Incidental findings on positron emission tomography/CT scans performed in the investigation of lung cancer. Br. J. Radiol. 229-237. doi: 10.1259/bjr/60606623. Chun-Sing, W., Nan-Jie, G., Yiu-Ching, C., 2014. Prevalence of synchronous second primary malignancy: Identification using whole body PET/CT imaging. Clin. Imaging. 179-186. doi: 10.1016/j.clinimag.2013.09.001. Czernin, J., Allen-Auerbach, M., Schelbert, H.R., 2007. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J. Nucl. Med. 48, 78-88. Dong, C., Hemminki, K., 2001. Second primary neosplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1995: A search for common mechanisms. Br. J. Cancer. 58, 997-1005. Duchateau, C.S., Stokkel, M.P., 2005. Second primary tumors involving nonsmall cell lung cancer: Prevalence and its influence on survival. Chest. 127, 1152-1158. Gill, R.S., Perry, T., Abele, J.T., Bedard, E.L., Schiller, D., 2012. The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules. World J. Surg. Oncol. 10, 25-32. doi: 10.1186/1477- 7819-10-25. Hayat, M.J., Howlader, N., Reichman, M.E., Edwards, B.K., 2007. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 12, 20-37. Kazama, T., Faria, S.C., Varavithya, V., Phongkitkarun, S., Ito, H., Macapinlac, H.A., 2005. FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls. Radiographics. 25, 191-207. Levi, F., Randimbison, L., Rafael, B.M., Manuela, M.C., La Vecchia, C., 2015. Second primary cancers in the Vaud and Neuchâtel Cancer. Eur. J. Cancer Prev. 24, 150-154. doi: 10.1097/CEJ.0000000000000085. Liu, Y.Y., Chen, Y.M., Yen, S.H., Tsai, C.M., Perng, R.P., 2002. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung. Cancer. 35, 189-194. Schoenberg, B.S., 1977. Multiple primary malignant neoplasms. The Connecticut experience, 1935-1964. Recent Results Cancer Res. 58, 1-173. Surapaneni, R., Singh, P., Rajagopalan, K., Hageboutros, A., 2012. Stage I lung cancer survivorship: Risk of second malignancies and need for individualized care plan. J. Thorac. Oncol. 7, 1252-1256. doi: 10.1097/JTO.0b013e3182582a79. Tatlidil, R., Jadavar, H., Bading, JR., Conti, P.S., 2002. Incidental colonic fluorodeoxyglucose uptake: Correlation with colonoscopic and histopathologic findings. Radiology. 224, 783-787. Teppo, L., Salminen, E, Pukkala, E., 2001. Risk of a new primary cancer among patients with lung cancer of different histological types. Eur. J. Cancer. 37, 613-619. Ueno, M., Muto, T., Oya, M., Ota, H., Azehura, K., Yamaguchi, T., 2003. Multiple primary cancer: An experience at the cancer institute hospital with special reference to colorectal cancer. Int. J. Clin. Oncol. 8, 162-167. Zhuang, H., Hickeson, M., Chacko, T.K., Duarte, P.S., Nakhoda, K.Z., Feng, Q., Alavi, A., 2002. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin. Nucl. Med. 27, 628-632
Yıl 2017, Cilt: 34 Sayı: 2, 137 - 140, 08.09.2017

Öz

Kaynakça

  • Chopra, A., Ford, A., De Noronha, R., Matthews, S., 2012. Incidental findings on positron emission tomography/CT scans performed in the investigation of lung cancer. Br. J. Radiol. 229-237. doi: 10.1259/bjr/60606623. Chun-Sing, W., Nan-Jie, G., Yiu-Ching, C., 2014. Prevalence of synchronous second primary malignancy: Identification using whole body PET/CT imaging. Clin. Imaging. 179-186. doi: 10.1016/j.clinimag.2013.09.001. Czernin, J., Allen-Auerbach, M., Schelbert, H.R., 2007. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J. Nucl. Med. 48, 78-88. Dong, C., Hemminki, K., 2001. Second primary neosplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1995: A search for common mechanisms. Br. J. Cancer. 58, 997-1005. Duchateau, C.S., Stokkel, M.P., 2005. Second primary tumors involving nonsmall cell lung cancer: Prevalence and its influence on survival. Chest. 127, 1152-1158. Gill, R.S., Perry, T., Abele, J.T., Bedard, E.L., Schiller, D., 2012. The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules. World J. Surg. Oncol. 10, 25-32. doi: 10.1186/1477- 7819-10-25. Hayat, M.J., Howlader, N., Reichman, M.E., Edwards, B.K., 2007. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 12, 20-37. Kazama, T., Faria, S.C., Varavithya, V., Phongkitkarun, S., Ito, H., Macapinlac, H.A., 2005. FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls. Radiographics. 25, 191-207. Levi, F., Randimbison, L., Rafael, B.M., Manuela, M.C., La Vecchia, C., 2015. Second primary cancers in the Vaud and Neuchâtel Cancer. Eur. J. Cancer Prev. 24, 150-154. doi: 10.1097/CEJ.0000000000000085. Liu, Y.Y., Chen, Y.M., Yen, S.H., Tsai, C.M., Perng, R.P., 2002. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung. Cancer. 35, 189-194. Schoenberg, B.S., 1977. Multiple primary malignant neoplasms. The Connecticut experience, 1935-1964. Recent Results Cancer Res. 58, 1-173. Surapaneni, R., Singh, P., Rajagopalan, K., Hageboutros, A., 2012. Stage I lung cancer survivorship: Risk of second malignancies and need for individualized care plan. J. Thorac. Oncol. 7, 1252-1256. doi: 10.1097/JTO.0b013e3182582a79. Tatlidil, R., Jadavar, H., Bading, JR., Conti, P.S., 2002. Incidental colonic fluorodeoxyglucose uptake: Correlation with colonoscopic and histopathologic findings. Radiology. 224, 783-787. Teppo, L., Salminen, E, Pukkala, E., 2001. Risk of a new primary cancer among patients with lung cancer of different histological types. Eur. J. Cancer. 37, 613-619. Ueno, M., Muto, T., Oya, M., Ota, H., Azehura, K., Yamaguchi, T., 2003. Multiple primary cancer: An experience at the cancer institute hospital with special reference to colorectal cancer. Int. J. Clin. Oncol. 8, 162-167. Zhuang, H., Hickeson, M., Chacko, T.K., Duarte, P.S., Nakhoda, K.Z., Feng, Q., Alavi, A., 2002. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin. Nucl. Med. 27, 628-632
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Bölüm Basic Medical Sciences
Yazarlar

Sibel Ucak Semirgin

Tarik Başoğlu Bu kişi benim

Murathan Sahin Bu kişi benim

Oktay Yapici Bu kişi benim

Yayımlanma Tarihi 8 Eylül 2017
Gönderilme Tarihi 7 Eylül 2017
Kabul Tarihi 30 Nisan 2015
Yayımlandığı Sayı Yıl 2017 Cilt: 34 Sayı: 2

Kaynak Göster

APA Ucak Semirgin, S., Başoğlu, T., Sahin, M., Yapici, O. (2017). Diagnostic value of FDG-PET/CT in the detection of synchronous cancers. Journal of Experimental and Clinical Medicine, 34(2), 137-140.
AMA Ucak Semirgin S, Başoğlu T, Sahin M, Yapici O. Diagnostic value of FDG-PET/CT in the detection of synchronous cancers. J. Exp. Clin. Med. Eylül 2017;34(2):137-140.
Chicago Ucak Semirgin, Sibel, Tarik Başoğlu, Murathan Sahin, ve Oktay Yapici. “Diagnostic Value of FDG-PET/CT in the Detection of Synchronous Cancers”. Journal of Experimental and Clinical Medicine 34, sy. 2 (Eylül 2017): 137-40.
EndNote Ucak Semirgin S, Başoğlu T, Sahin M, Yapici O (01 Eylül 2017) Diagnostic value of FDG-PET/CT in the detection of synchronous cancers. Journal of Experimental and Clinical Medicine 34 2 137–140.
IEEE S. Ucak Semirgin, T. Başoğlu, M. Sahin, ve O. Yapici, “Diagnostic value of FDG-PET/CT in the detection of synchronous cancers”, J. Exp. Clin. Med., c. 34, sy. 2, ss. 137–140, 2017.
ISNAD Ucak Semirgin, Sibel vd. “Diagnostic Value of FDG-PET/CT in the Detection of Synchronous Cancers”. Journal of Experimental and Clinical Medicine 34/2 (Eylül 2017), 137-140.
JAMA Ucak Semirgin S, Başoğlu T, Sahin M, Yapici O. Diagnostic value of FDG-PET/CT in the detection of synchronous cancers. J. Exp. Clin. Med. 2017;34:137–140.
MLA Ucak Semirgin, Sibel vd. “Diagnostic Value of FDG-PET/CT in the Detection of Synchronous Cancers”. Journal of Experimental and Clinical Medicine, c. 34, sy. 2, 2017, ss. 137-40.
Vancouver Ucak Semirgin S, Başoğlu T, Sahin M, Yapici O. Diagnostic value of FDG-PET/CT in the detection of synchronous cancers. J. Exp. Clin. Med. 2017;34(2):137-40.